These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26555944)

  • 1. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
    Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
    Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
    Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
    Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation.
    Bailly E; Ville S; Blancho G; Morelon E; Bamoulid J; Caillard S; Chatelet V; Malvezzi P; Tourret J; Vuiblet V; Anglicheau D; Bertrand D; Grimbert P; Haidar F; Hazzan M; Kamar N; Merville P; Mousson C; Pernin V; Pouteil-Noble C; Purgus R; Sayegh J; Westeel PF; Sautenet B; Gatault P; Büchler M
    Transpl Int; 2020 Jul; 33(7):786-795. PubMed ID: 32279367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antibody mediated rejection shortly after acute cellular rejection in a pediatric kidney transplantation recipient.
    Okada M; Kamei K; Matsuoka K; Ito S
    CEN Case Rep; 2018 Nov; 7(2):288-291. PubMed ID: 29949115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes.
    Garrouste C; Canaud G; Büchler M; Rivalan J; Colosio C; Martinez F; Aniort J; Dudreuilh C; Pereira B; Caillard S; Philipponnet C; Anglicheau D; Heng AE
    Transplantation; 2017 Mar; 101(3):649-656. PubMed ID: 27043407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
    Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
    Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
    Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
    Woodle ES; First MR; Pirsch J; Shihab F; Gaber AO; Van Veldhuisen P;
    Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.